Nick G. Vatakis, M.D.
Specialist
Medicare and federal program status
Opted out of Medicare from December 23, 2019 through December 23, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly.
Source: CMS Medicare Opt Out Affidavits (record last updated January 15, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
NY license 191863
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clonazepam Other prescribers in New York, NY | 68 |
| Zolpidem Tartrate Other prescribers in New York, NY | 49 |
| Trazodone Hcl Other prescribers in New York, NY | 41 |
| Lorazepam Other prescribers in New York, NY | 36 |
| Lamotrigine Other prescribers in New York, NY | 28 |
| Bupropion Xl (bupropion hcl) Other prescribers in New York, NY | 27 |
| Sertraline Hcl Other prescribers in New York, NY | 24 |
| Lurasidone Hcl Other prescribers in New York, NY | 21 |
| Rexulti (brexpiprazole) Other prescribers in New York, NY | 21 |
| Duloxetine Hcl Other prescribers in New York, NY | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $682,320 in research payments for these studies, mostly to the institutions running them.
- A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A phase 4 openlabel study to evaluate the safety and tolerability of daily dosing of rimegepant in episodic migraine prevention
Pfizer Inc. - A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
AbbVie Inc. · Terminated · NCT05941442 - An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047457 - ITI-007-505
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - A randomized double-blind placebo-controlled multicenter study to assess the efficacy and safety of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.